ASAndrew John Swarts

Andrew John Swarts

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew John Swarts has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Highly Efficient Transfer Hydrogenation of Alkenes With Ammonia Borane Mediated by a Simple Ni(II) Catalyst System

    by Vincent Vermaak, M. Cassiem Joseph, Pamela Moyo, Hermanus C. M. Vosloo, Andrew J. Swarts

    A practical nickel platform for transfer hydrogenation (TH) of alkenes using ammonia borane (AB) is described. With NiCl 2 ·6H 2 O/ethylenediamine ( L2 ) at 25–50 °C, aromatic and aliphatic alkenes reduce rapidly and α,β‐unsaturated esters undergo chemoselective C═C hydrogenation; at low loading the system achieves turnover number up to 3960. Discrete Ni(II) complexes, C1–C4 , mirror the behavior of in situ Ni/ L systems, indicating common active species. Mechanistic studies reveal that AB initiates catalysis by converting Ni(II) to Ni(0), while AB dehydrogenation supplies H 2 required for hydrogenation. Ni–H signatures appear only under specific ligand environments ( L1 ) and are transient on the NMR timescale; L2 promotes efficient initiation without detectable hydride resting states. Hg‐drop tests, observation of ligand dissociation/nickel black, AB‐purity effects, DLS, and TEM analyses confirm catalyst evolution to nickel‐containing particulate material after catalysis, while the collective mechanistic data support AB‐mediated activation of Ni(II) precatalysts and hydrogenation in the presence of H 2 generated from AB. The method uses earth‐abundant nickel, bench‐stable AB, and simple ligands to deliver fast, scalable TH under mild conditions.

  • Open Access

    A spectroscopic and in silico study on ruthenium( ii ) complexes bearing pyridine–carboxamide ligands interacting with DNA as potential therapeutics

    by Sheldon Sookai, Pamela. S. Moyo, Monika Nowakowska, Andrew J. Swarts

    Two half-sandwich ruthenium( ii ) complexes (C1 and C2) bearing N , N -chelating picolinamide ligands were synthesised and comprehensively characterised to elucidate the role of ligand electronics in governing stability and DNA interactions.

  • Open Access

    Synthesis, Electrochemistry, In Vitro Antiprotozoal Efficacy and Mechanistic Study of Novel ‘Ferrantoin’ and Related Derivatives

    by Maryna Saayman, Janine Aucamp, Helena D. Janse van Rensburg, Christina Kannigadu, Rotondwa Mphephu, Andrew J. Swarts, Keisuke Suganuma, David D. N'DA

    African trypanosomiasis and leishmaniasis are vector‐borne infectious diseases that affect both humans and animals. If left untreated, these neglected tropical diseases can be fatal. There are tens to thousands of new cases of both diseases reported by the WHO annually. The clinically available treatments are not practical because they suffer from severe adverse effects, impractical administration and increased instances of parasitic resistance. This emphasises the need for the development of new drugs to treat these diseases. In the search for such drugs, we investigated a series of ferrocenyl‐based hydantoin/rhodanine derivatives. Herein, we report the design, synthesis, electrochemistry and in vitro biological activity of these derivatives against amastigotes of Leishmania donovani , as well as blood‐stage trypomastigotes of Trypanosoma brucei brucei , Trypanosoma brucei gambiense , Trypanosoma brucei rhodesiense , Trypanosoma equiperdum and Trypanosoma evansi . Ferrocenylrhodanine analogues 19 and 23 were identified as a potential leishmanicidal early lead and hit, respectively, whereas 3‐hydantoin‐containing analogue 11 was identified as an antileishmanial hit. Ferrocene derivatives 23 and 11 were tested for ROS activity, and mitochondrial dysfunction is suspected to play a role in their mechanisms of action. Nine trypanosomacidal hits were also identified, of which ferrocenylrhodanine analogue 21 was the most prominent. These compounds are accordingly suited for further investigation as antitrypanosomatid drugs in the future. This may include increasing compound stability and solubility.

  • Open Access

    Pyrazolyl–Pyridine Ruthenium Complexes: A New Metallic Line of Defense Against Acinetobacter baumannii

    by M. Cassiem Joseph, Sheldon Sookai, Monika Nowakowska, Rotondwa Mphephu, Angela M. Kavanagh, Johannes Zuegg, Mark A. T. Blaskovich, Andrew J. Swarts

    The emergence of antimicrobial resistance (AMR), especially among ESKAPE infections, highlights the pressing necessity for novel chemical frameworks with atypical modes of action. Transition‐metal complexes have emerged as attractive possibilities owing to their varied geometries, redox activity, and capacity to interact with biological sites inaccessible to traditional chemical antibiotics. This study presents the antibacterial and antifungal assessment of a series of Ru(II) pyrazolyl–pyridine half‐sandwich complexes ( C1 – C6 ), thereby broadening the chemical scope of metalloantibiotics previously investigated inside pyridyl–1,2,3‐triazolyl frameworks. The compounds were synthesized with good yields and structurally validated by single‐crystal X‐ray diffraction, demonstrating piano‐stool topologies with unique ligand‐dependent anion orientations. Extensive biological screening via the Community for Open Antimicrobial Drug Discovery (CO‐ADD) platform revealed selective efficacy of complexes C1 – C3 against Acinetobacter baumannii, a significant multidrug‐resistant pathogen. Cytotoxicity and hemolysis assessments revealed advantageous therapeutic ranges for the most potent combinations. Biophysical investigations, encompassing DNA‐binding fluorescence displacement, linear dichroism, and in silico molecular docking and dynamics, elucidated that the lead drug interacts with bacterial DNA via partial intercalation and groove contacts. Collectively, our findings establish Ru(II) pyrazolyl–pyridine complexes as prospective candidates for the advancement of next‐generation metalloantibiotics and underscore the significance of coordination‐chemistry‐driven approaches in addressing AMR.


  • Open Access

    Unveiling Solvent‐Dependent Divergent Hydrogen Production Pathways during the Dehydrogenation of Formic Acid Using N,N′‐Iminopyridine Ruthenium(II) Complexes

    by Thabiso Mphuti, Rotondwa Mphephu, Moegamat Joseph, Andrew J. Swarts

    The preparation of a panel of cationic, half‐sandwich iminopyridine ruthenium(II) complexes of the type [(L1)RuCl(p‐cymene)]Cl (C1–C11) is reported, where L = substituted N‐phenyl‐1‐(2‐pyridinyl)methanimine ligand derivates (L1–L9) and their efficiency in the catalytic dehydrogenation of formic acid (FA). The activity could be correlated with the nature of the substituent on the imine nitrogen and the solubility of the complexes in water, with C1 exhibiting the highest initial turnover frequency (TOF) of 281 hr−1 at 90 °C. Kinetic and mechanistic investigations are undertaken in dimethyl sulfoxide (DMSO) and H2O, revealing that the proton source in the hydrogen production step is solvent‐dependent. FA is found to be responsible for H2 formation in DMSO, and H3O+ ions are involved in generating H2 in water. Complex C1 is more stable in water, as it maintains efficient gas evolution for 16 cycles without any deactivation, reaching a turnover number (TON) of 13 791. Furthermore, C1 is active, although with reduced activity (TOF = 43 hr−1), for over 34 h when operated under continuous FA addition conditions.


  • Pyrazolyl‐Pyridine Ruthenium (II) Catalysts for Selective Hydrogen Generation Through Formic Acid Dehydrogenation

    by Rotondwa Mphephu, M. Cassiem Joseph, Andrew John Swarts

    A series of pyridine‐pyrazolyl Ru(II) p‐cymene complexes of the type [RuCl(p‐cymene)L]X (C1–C7, X = Cl, BPh4 or PF6), featuring different electronic and steric properties, are prepared by the reaction of 3,5‐disubstituted pyrazolyl‐pyridine ligands (L1–L3) with [Ru(p‐cymene)Cl2]2 followed by salt metathesis with NaBPh4 or AgPF6. The complexes, upon activation with formate, show activity toward the dehydrogenation of formic acid (FA) to produce equimolar quantities of H2 and CO2. In optimization studies, kinetic and thermodynamic investigations provide insight into the role of pre‐catalyst and FA in the catalytic process. It is demonstrated that the most active catalyst derived from C4, could dehydrogenate FA to CO2 and H2 in quantitative yields within 1 h with tons and TOFs of ≈1032 and ≈1238 h−1, respectively. Reactivity patterns are rationalized based on electronic properties and our understanding of ion pairing in related compounds. Reactivity studies between C4 and HCOOK provide evidence for the key Ru‐monohydride species involved in catalysis.


  • Open Access

    Formic Acid Dehydrogenation Catalysis Using Novel Pyridyl‐Formamidine Half‐Sandwich Ruthenium(II) Complexes

    by Juliana Mana Edor, M. Cassiem Joseph, Johan H. L. Jordaan, Hermanus C. M. Vosloo, Andrew J. Swarts

    The reaction of N,N′‐bidentate chelating ligands with [Ru(p‐cymene)Cl2]2 in methanol resulted in six‐membered Ru complexes with tshe general formula [RuCl(p‐cymene)L]Cl exhibiting a pseudo‐octahedral piano‐stool geometry. The combination of NMR, MS, FTIR and SCXRD techniques confirmed the successful synthesis of the reported compounds. The prepared complexes were all active in formic acid dehydrogenation (FADH) catalysis, producing an equimolar mixture of H2 and CO2 gases with no detectable amount of CO. Establishing thermodynamic and kinetic parameters provided evidence for the role of pre‐catalyst and FA during catalysis. Reactivity studies between C6 and HCOOK revealed complex equilibria and allowed for the detection of the key monohydride species involved in catalysis. Remarkably, C6 proved to be robust at 100°C, resulting in approximately 98% substrate conversion with a total TON of about 7892 and TOF close to 300 h−1 after 35 h.


  • Open Access

    Synthesis, Characterisation, and Coordination Behaviour of Novel Pyridyl‐formamidine Based Mn(I), Cu(II), Zn(II), and Pd(II) Complexes

    by Juliana Mana Edor, M. Cassiem Joseph, Johan H. L. Jordaan, Hermanus C. M. Vosloo, Andrew J. Swarts

    We report a new synthetic approach for the synthesis of less‐explored unsymmetrical pyridyl‐formamidine ligands and their coordination behaviour to form Mn(I), Cu(II), Zn(II), and Pd(II) complexes. The one‐step process for synthesising the unsymmetrical pyridyl‐formamidine compounds offers the advantage of being functional‐group tolerant and less cumbersome. Generally, the pyridyl‐formamidine ligands coordinate to the metal centres in a bidentate fashion to form a six‐membered chelate as established by spectroscopic and crystallographic analysis. It was observed that the formamidine functionality is prone to hydrolysis in the presence of methoxy substituent on the phenyl ring and/or acetate‐containing metal precursors.


  • Open Access

    The Antimicrobial Properties of PdII− and RuII−pyta Complexes**

    by Annick van Niekerk, M. Cassiem Joseph, Angela Kavanagh, Hue Dinh, Andrew J. Swarts, Selwyn F. Mapolie, Johannes Zuegg, Amy K. Cain, Alysha G. Elliott, Mark A. T. Blaskovich, et al.

    Infections associated with antimicrobial resistance (AMR) are poised to become the leading cause of death in the next few decades, a scenario that can be ascribed to two phenomena: antibiotic over‐prescription and a lack of antibiotic drug development. The crowd‐sourced initiative Community for Open Antimicrobial Drug Discovery (CO‐ADD) has been testing research compounds contributed by researchers around the world to find new antimicrobials to combat AMR, and during this campaign has found that metallodrugs might be a promising, yet untapped source. To this end, we submitted 18 PdII− and RuII−pyridyl−1,2,3‐triazolyl complexes that were developed as catalysts to assess their antimicrobial properties. It was found that the Pd complexes, especially Pd1, possessed potent antifungal activity with MICs between 0.06 and 0.125 μg mL−1 against Candida glabrata. The in‐vitro studies were extended to in‐vivo studies in Galleria mellonella larvae, where it was established that the compounds were nontoxic. Here, we effectively demonstrate the potential of PdII−pyta complexes as antifungal agents.